医学
慢性阻塞性肺病
恶化
氧气疗法
队列
内科学
队列研究
重症监护医学
人口
门诊部
急诊医学
儿科
环境卫生
作者
Yet H. Khor,Andreas Palm,Alyson W. Wong,Sabina A. Guler,Filip Björklund,Zainab Ahmadi,Josefin Sundh,Christopher J. Ryerson,Magnus Ekström
出处
期刊:Thorax
[BMJ]
日期:2025-03-20
卷期号:: thorax-221063
标识
DOI:10.1136/thorax-2023-221063
摘要
Background Long-term oxygen therapy (LTOT) improves survival in patients with chronic severe resting hypoxaemia, but effects on hospitalisation are unknown. This study evaluated the potential impact of starting LTOT on acute exacerbation and hospital burden in patients with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and pulmonary hypertension (PH). Methods Longitudinal analysis of consecutive patients in the population-based Swedish DISCOVERY cohort who started LTOT between 2000 and 2018 with a follow-up duration≥3 months. Total and hospitalised acute exacerbations of the underlying disease, all-cause hospitalisations, and all-cause outpatient visits were annualised and compared between the year before and after LTOT initiation for each disease cohort, and by hypercapnic status in patients with COPD. Results Patients with COPD (n=10 134) had significant reduction in annualised rates of total and hospitalised acute exacerbations, as well as all-cause hospitalisations, following LTOT initiation, with increment in those with ILD (n=2507) and PH (n=850). All-cause outpatient visits increased across all cohorts following LTOT initiation. Similar findings were observed in patients with hypercapnic and non-hypercapnic COPD. Sensitivity analyses of patients with 12 months of follow-up showed reduced acute exacerbations and all-cause hospitalisations in the ILD and PH cohorts. Conclusion LTOT is associated with reduced rates of both total and hospitalised acute exacerbations and all-cause hospitalisations in patients with COPD, as well as patients with ILD and PH with 12 months of follow-up. There is increased all-cause outpatient visits in all disease groups following LTOT initiation.
科研通智能强力驱动
Strongly Powered by AbleSci AI